NAD refers skin care claims to FDA
This article was originally published in The Tan Sheet
National Advertising Division finds Pinnacle Marketing has "failed to provide any substantiating information" for its Acadia Skin Care product and has thus referred the case to FDA. In an upcoming NAD Case Report, Council of Better Business Bureaus division challenges print ads claiming Acadia "will help relieve the irritation and embarrassment of psoriasis, eczema, seborrheic dermatitis, rough, dry skin and dandruff," and that product's "active ingredients are FDA approved." In response, Pinnacle maintained claims at issue could be substantiated but said it would not do so "for economic reasons"...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.